In line with its strategic plan of consolidation in key markets and the opening of new subsidiaries, Burdinola takes a further step forward with the opening of this new subsidiary in a strategic market for the sector.
With this new subsidiary, Burdinola will further strengthen its international presence and consolidate its position in the market as an innovative and reliable partner for its customers worldwide.
Burdinola’s most important asset is the satisfaction of its customers, being able to demonstrate that 100% of the customers who have responded to the satisfaction survey in the last 8 years would recommend Burdinola.
Since its creation, the new subsidiary will maintain a line of work in line with Burdinola’s global strategy, centred on its positioning in safe and efficient laboratories, and focused on attracting large projects. Its specialisation in safe laboratories provides differentiation and added value to its technical proposal. Burdinola has been present in the Swiss market for years, with major references such as Ferring Pharmaceuticals, AC Immune, Debiopharm, Dsm-firmenich, CHUV (Lausanne University Hospital Research Center) and AdipoGen Life Sciences, among others.
Pablo Corcuera, until now director of Burdinola France, will also take over the management of the new subsidiary in Switzerland. With the new Swiss subsidiary, the company aims to position itself as a leader in a market in which it has good growth forecasts and to consolidate its leadership in Europe by being the leader in the European countries in which it is present.
Burdinola is a cooperative society, leader in its sector, specialised in the planning, integration and installation of laboratories from a global vision. In more than 40 years of experience, they have equipped nearly 8,000 laboratory projects in more than 50 countries in sectors such as pharmaceuticals, cosmetics, education, nutrition, research and testing, chemicals, petrochemicals, education, industry and healthcare.
Burdinola is currently the absolute leader in the national market and leader in private projects in countries such as France, Belgium, Colombia and Peru. The geographical diversity of its projects means that it currently has 5 branches in Spain, as well as subsidiaries in France, Benelux, Italy, Dubai, Mexico, Peru and Colombia and distributors in many countries. In addition to all of them, this year we have a new subsidiary in Switzerland, a key country in the pharmaceutical industry, which is one of the largest and most important in the world and the world leader in R&D investment.
The pharmaceutical sector is a highly specialised sector where laboratories have a high level of demand in all parameters and where Burdinola is consolidated as a specialist providing solutions for the complete functional integration of people, spaces, processes and equipment.
